Bernadette Connaughton - Oct 1, 2025 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Role
Director
Signature
/s/ James Oehler, Attorney-in-Fact
Stock symbol
HALO
Transactions as of
Oct 1, 2025
Transactions value $
-$150,481
Form type
4
Date filed
10/1/2025, 06:29 PM
Previous filing
Sep 2, 2025
Next filing
Nov 12, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Connaughton Bernadette Director C/O HALOZYME THERAPEUTICS, INC., 12390 EL CAMINO REAL, SAN DIEGO /s/ James Oehler, Attorney-in-Fact 2025-10-01 0001662521

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HALO Common Stock Sale -$113K -1.5K -3.19% $75.09 45.5K Oct 1, 2025 Direct F1, F2
transaction HALO Common Stock Sale -$37.9K -500 -1.1% $75.70 45K Oct 1, 2025 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1.
F2 Represents a weighted average sales price per share. The shares were sold at prices ranging from $74.64 to $75.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 Represents a weighted average sales price per share. The shares were sold at prices ranging from $75.64 to $75.92. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.